ClinicalTrials.gg
RecruitingNCT07530510Updated Nov 18, 2026

KPAP vs EPR for Comfort

An interventional study of APAP + KPAP and APAP + EPR in Obstructive Sleep Apnea, sponsored by SleepRes Inc.. Recruiting at 1 site in United States. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by SleepRes Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 755 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 162 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Planned enrollment
423rd of 596
24 · median 49
Started
2026
with 41 others
No phase
412 of 755
68 open now
Primary completion
2027-07
later than 96 of 161 live
Registered
731st of 755
by date

Among the 755 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 423rd largest by planned enrollment of the 596 interventional ones that give a count, is one of 42 that started in 2026, is one of 412 with no phase, reaches primary completion later than 96 of the 161 other live ones, and was the 731st registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

127 of the 755 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 755 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

The KPAP EPR Home is a randomized, crossover study in which subjective comfort will be compared between SleepRes APAP + KPAP and ResMed APAP + EPR. Participants will be individuals with newly diagnosed OSA who have not previously tried any PAP treatment (PAP-naïve).

Upon signing an informed consent, participants will be randomized to receiving either APAP + KPAP (delivered by a SleepRes device) or APAP + EPR (delivered by a ResMed device) for home use. Participants will be asked to use the devices (in the order of randomization) for 4 days each, with 3 days of washout in between. Participants will be blinded to the sequence order, even though they will receive machines that are not identical at each treatment. The KPAP drop will be set to the maximum level (i.e., 5 cmH2O), while EPR will be set on 3. APAP will be set on the full pressure range (i.e., 5-20 cmH2O). After each period, each individual will be asked to rate their device preference according to a 10-point visual analog (VAS) scale (i.e., 1=extremely uncomfortable treatment; 10=extremely comfortable treatment). After usage, the devices will be returned to the office and device data will be downloaded.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • above 18 kg/m2, inclusive
  • Recent formal diagnosis of OSA meeting all the following criteria: AHI > 10, Central apneas \< 25% of events, PLM arousal index \< 15, no prior/concomitant OSA therapy
  • Subject is fluent in English and subject understands the study protocol and is willing and able to comply with study requirements and sign .
  • Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • A female of that is pregnant or intends to become pregnant.
  • Any unstable or severe medical condition of any organ system including congestive heart failure, , renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).
  • Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.
  • The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc.).
  • The presence of a psychiatric disorder, including attempted suicide within 1 year prior to screening, or current suicidal ideation.
  • A serious illness or infection in the past 30 days.
  • Excessive alcohol consumption (>21 drinks/week).
  • The use of any illegal drug(s).
  • Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    APAP + KPAP

    Auto-adjusting positive airway pressure + Kairos positive airway pressure

    Device: APAP + KPAP

  • Active comparator
    APAP + EPR

    Auto-adjusting positive airway pressure + Expiratory pressure relief

    Device: APAP + EPR

Interventions

  • DeviceAPAP + KPAP

    A SleepRes device will deliver auto-adjusting positive airway pressure (APAP) + Kairos PAP at the maximum drop (1, 2, 3, 4, 5 cmH2O at background pressures of 6, 7, 8, 9, 10 cmH2O, respectively)

  • DeviceAPAP + EPR

    A ResMed device will deliver auto-adjusting positive airway pressure (APAP) + Expiratory Pressure Relief set on level 3

06

What researchers measure

Primary outcomes

  1. Subjective comfort

    This outcome will be evaluated through a 10 point Visual Analog Scale (VAS)

    Time frame: This outcome will be evaluated after 4 days of treatment in each arm

Secondary outcomes

  1. P95

    Pressure delivered by the device for 95% of the time. It will be downloaded from the device.

    Time frame: This outcome will be evaluated after 4 days of treatment in each arm

  2. Residual AHI

    Apnea hypopnea index downloaded from the device

    Time frame: This outcome will be evaluated after 4 days of treatment in each arm

  3. Adherence (in average h/night)

    Use of the device per night downloaded from the device

    Time frame: This outcome will be evaluated after 4 days of treatment in each arm

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — We only plan to share the results after we publish them.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 8 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Jun 2026 → Nov 2026, primary completion Dec 2026 → Jul 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Nov 1, 2026was Jun 2026
Primary completionEst.
Jul 1, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in United States
Show site
  • Sleep Centers of Middle Tennessee · Murfreesboro, United States
Nov 18, 2026
Start date
Jun 1, 2026→Nov 1, 2026 (actual)
Nov 18, 2026
Primary completion
Dec 1, 2026→Jul 1, 2027
Nov 18, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Sleep Centers of Middle Tennessee · Murfreesboro, United States
    Start date Jun 1, 2026→Nov 1, 2026 (now actual)
    Primary completion Dec 1, 2026→Jul 1, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07530510
Lead sponsor
SleepRes Inc.
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Nov 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

William Noah, MD
Contact
whnoah@sleepres.com
6153946624

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion